Residency · Residency · Medicine Pediatrics
Juvenile Idiopathic Arthritis to Adult Rheumatic Disease
Overview
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood, affecting ~1 in 1,000 children. JIA is defined as arthritis of unknown etiology beginning before age 16 and persisting >= 6 weeks (ILAR classification) JIA is not simply "childhood rheumatoid arthritis" — it encompasses distinct subtypes with different pathophysiology, outcomes, and adult equivalents. Up to 50% of JIA patients have active disease persisting into adulthood, requiring lifelong management and successful transition to adult rheumatology.
ILAR Classification of JIA Subtypes
| Subtype | Frequency | Onset/Demographics | Key Features | Adult Equivalent |
|---|---|---|---|---|
| Oligoarticular | ~50% | Age 2-4; F:M 4:1 | ≤4 joints; high uveitis risk (ANA+) | No true equivalent |
| Polyarticular RF(-) | ~20% | Variable; F>M | ≥5 joints; symmetric | Seronegative RA |
| Polyarticular RF(+) | ~5% | Late childhood/adolescence; F>M | ≥5 joints; erosive | Adult RA (identical) |
| Systemic JIA | ~10% | Any age; M=F | Quotidian fever, rash, serositis; MAS risk | Adult-onset Still disease |
| Enthesitis-related (ERA) | ~10% | Older boys; HLA-B27+ | Lower extremity, SI joints, enthesitis | Ankylosing spondylitis |
| Psoriatic JIA | ~5% | Bimodal; any age | Dactylitis, nail pitting, psoriasis | Psoriatic arthritis |
Oligoarticular JIA (Most Common, ~50%)
<= 4 joints affected in first 6 months. Persistent oligoarticular: remains <= 4 joints throughout disease course. Extended oligoarticular: expands to >4 joints after 6 months. Peak onset: 2-4 years; female predominance (4:1) High risk of chronic anterior uveitis (especially ANA-positive patients) Generally good articular prognosis if persistent; extended form has worse outcomes. No true adult equivalent — some evolve into spondyloarthropathy or undifferentiated arthritis.
Polyarticular JIA (RF-Negative, ~20%)
>= 5 joints in first 6 months; RF negative; Variable age of onset; female predominance; Symmetric small and large joint involvement; Better prognosis than RF-positive polyarticular JIA; Adult equivalent: seronegative RA or undifferentiated polyarthritis.
Polyarticular JIA (RF-Positive, ~5%)
>= 5 joints; RF positive on 2 occasions >= 3 months apart. Older onset (late childhood/adolescence); female predominance. Essentially identical to adult rheumatoid arthritis. Symmetric small joint polyarthritis, rheumatoid nodules possible. Aggressive erosive disease; poorest articular prognosis of all subtypes.
Systemic JIA (sJIA, ~10%)
Quotidian fever (daily spikes >=39C returning to baseline) plus arthritis plus >= 1 of: evanescent rash, hepatosplenomegaly, serositis, generalized lymphadenopathy. No sex predilection; any age in childhood. Autoinflammatory (innate immunity driven) rather than autoimmune. Complications: macrophage activation syndrome (MAS), growth failure, amyloidosis. Adult equivalent: adult-onset Still disease (same disease spectrum) Treatment targets IL-1 and IL-6 pathways.
Enthesitis-Related Arthritis (ERA, ~10%)
Arthritis + enthesitis (inflammation at tendon/ligament insertions) Older boys predominantly; HLA-B27 positive in many. Involves lower extremity large joints, sacroiliac joints, spine. Adult equivalent: ankylosing spondylitis and other spondyloarthropathies. Associated with acute anterior uveitis (not chronic like oligoarticular)
Psoriatic JIA (~5%)
Arthritis + psoriasis, or arthritis + >= 2 of: dactylitis, nail pitting/onycholysis, psoriasis in first-degree relative. Can affect any age; bimodal distribution. Adult equivalent: psoriatic arthritis.
<image>Classification of JIA subtypes showing age of onset, sex predominance, joint pattern, key laboratory and clinical features, and corresponding adult rheumatic disease equivalents for each category</image>
Uveitis in JIA
Chronic Anterior Uveitis
Silent — often asymptomatic until vision loss occurs; requires screening. Highest risk: oligoarticular JIA, ANA-positive, young age at onset, female. Can cause posterior synechiae, band keratopathy, cataracts, glaucoma, vision loss. Screening schedule (AAP/ACR): High risk (oligoarticular/polyarticular, ANA+, onset <7 years): ophthalmology every 3 months. Moderate risk: every 6 months. Continue screening for years even if arthritis is in remission (uveitis can persist independently) Treatment: topical corticosteroids, methotrexate (steroid-sparing), adalimumab (anti-TNF with best evidence for JIA uveitis)
Acute Anterior Uveitis
Seen in enthesitis-related arthritis (HLA-B27 associated); Symptomatic: red, painful eye with photophobia; Episodic, unilateral; Treatment: topical steroids and cycloplegics.
Medical Management of JIA
First-Line: NSAIDs
Naproxen, ibuprofen, meloxicam; May be sufficient for mild oligoarticular JIA; Bridge therapy while waiting for DMARD effect; Not disease-modifying — do not prevent joint damage.
Intra-Articular Corticosteroid Injections
Triamcinolone hexacetonide preferred (longer duration of response) First-line for oligoarticular JIA — can achieve prolonged remission. Performed under sedation or general anesthesia in young children. Can be repeated but risk of subcutaneous atrophy, cartilage damage with excessive use.
Conventional DMARDs
Methotrexate: cornerstone of JIA treatment; weekly oral or subcutaneous; 10-15 mg/m2/week. Effective for polyarticular and extended oligoarticular JIA. Side effects: nausea (dose-limiting in children), hepatotoxicity, bone marrow suppression, teratogenicity. Folic acid supplementation reduces side effects. Sulfasalazine: used in ERA/spondyloarthropathy subtype. Leflunomide: alternative to methotrexate.
Biologic DMARDs
Anti-TNF agents: Etanercept: approved for JIA >= 2 years; widely used first-line biologic; Adalimumab: approved for JIA >= 2 years; preferred for JIA-associated uveitis; Infliximab: used off-label; IL-6 inhibitors: Tocilizumab: approved for sJIA >= 2 years and polyarticular JIA >= 2 years; dramatic efficacy in sJIA. IL-1 inhibitors: Anakinra: rapid onset; used for sJIA and MAS; daily injection; Canakinumab: approved for sJIA >= 2 years; monthly injection; T-cell costimulation blocker: Abatacept: approved for polyarticular JIA >= 2 years; alternative to anti-TNF; JAK inhibitors: tofacitinib approved for polyarticular JIA >= 2 years; oral small molecule.
<image>Stepwise treatment algorithm for JIA showing escalation from NSAIDs through intra-articular steroids, methotrexate, biologic DMARDs, and combination therapy with specific subtype considerations</image>
Macrophage Activation Syndrome (MAS)
Overview
Life-threatening complication of sJIA (occurs in ~10%; subclinical MAS may be more common) Form of secondary HLH. Triggered by disease flare, infection (especially EBV), or medication changes.
Clinical Features
Persistent non-remitting fever (contrast with quotidian fever of sJIA); Hepatosplenomegaly, lymphadenopathy; Hemorrhagic manifestations (DIC); Encephalopathy, multi-organ failure.
Laboratory Hallmarks
Paradoxical drop in ESR (falling fibrinogen, a key distinguishing feature); Markedly elevated ferritin (often >10,000; ferritin >684 in sJIA is 96% specific for MAS) Elevated LDH, AST/ALT, triglycerides; Falling platelets, WBC, hemoglobin (cytopenias); Low/falling fibrinogen; elevated D-dimer (DIC); Elevated soluble IL-2 receptor.
Management
High-dose pulse methylprednisolone (30 mg/kg, max 1g, daily x 3-5 days) Cyclosporine A. Anakinra (IL-1 blockade): increasingly used as first-line, especially if MAS triggered by sJIA flare. Emapalumab (anti-interferon-gamma): approved for primary HLH; used in refractory MAS. Treat underlying trigger; ICU admission for severe cases.
Transition to Adult Care
Disease Trajectory into Adulthood
~50% of JIA patients have active disease into adulthood. RF-positive polyarticular and extended oligoarticular have highest persistence rates. Patients may present to adult rheumatologists with joint damage from childhood disease. sJIA: many achieve remission but some evolve into chronic destructive arthritis; adult-onset Still disease is the same spectrum.
Transition Challenges
Loss to follow-up during transition: up to 50% in some cohorts. Poor self-management skills if always parent-managed. Medication adherence declines in adolescence. Uveitis screening must continue — easy to lose track during transition. Reproductive health: methotrexate teratogenicity; biologics in pregnancy (certolizumab is the preferred anti-TNF as it does not cross the placenta)
Best Practices
Begin transition planning at age 12-14. Graduated independence in clinic visits (time alone with provider) Disease self-management education: medication names, doses, side effects, warning signs. Transfer of comprehensive medical summary including subtype, treatment history, complications, uveitis screening status. Joint clinic model or warm handoff preferred.
<image>Comparison of JIA subtypes showing long-term outcomes into adulthood including remission rates, risk of ongoing disease activity, joint damage, and functional disability by subtype</image>
Clinical Pearls
JIA is a diagnosis of exclusion — always rule out septic arthritis, malignancy (leukemia can mimic JIA with bone pain, limp, and joint swelling), reactive arthritis, and Lyme disease. The "ANA-positive young girl with oligoarticular JIA" phenotype is the highest risk for chronic anterior uveitis — ophthalmology screening is non-negotiable. Ferritin trending from elevated to very elevated (with falling ESR) in a child with sJIA should trigger urgent evaluation for MAS. Methotrexate-associated nausea in children often causes anticipatory nausea (conditioned response) — behavioral interventions and subcutaneous administration help. RF-positive polyarticular JIA IS childhood RA — treat aggressively with DMARDs and biologics to prevent erosive damage. HLA-B27 positivity in a boy with enthesitis-related arthritis predicts axial involvement and adult ankylosing spondylitis — counsel regarding long-term expectations. Biologic therapy started in childhood requires pregnancy planning discussions in adolescence — build this into transition conversations.
References
- Ravelli A, Martini A. Juvenile Idiopathic Arthritis. Lancet. 2007;369(9563):767-778.
- Ringold S, Angeles-Han ST, Engel ME, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis. Arthritis Care Res. 2019;71(6):717-734.
- Angeles-Han ST, Ringold S, Engel ME, et al. 2019 ACR/AF Guideline for the Screening, Monitoring, and Treatment of JIA-Associated Uveitis. Arthritis Care Res. 2019;71(6):703-716.
- Minoia F, Davi S, Horne A, et al. Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2014;66(11):3160-3169.
